EDITORIAL: Eli Lilly’s cuts are necessary evil
If Eli Lilly and Co. sneezes, Indianapolis catches a cold. The statement has been so oft-repeated that it’s become a cliché.
Home » Search
Search Results
4,409 results for '\"eli lilly\"'
- Sort By
-
Date
- Any Time
- Past Day
- Past Week
- Past Month
- Past Year
-
Custom Date Range
Articles
PROXY CORNER: Eli Lilly and Co.
Indianapolis-based Eli Lilly and Co. discovers, develops, manufactures and sells pharmaceutical products for humans and animals.
Eli Lilly’s profit shoots up despite lackluster sales
The Indianapolis pharmaceutical company left its full-year profit forecast unchanged despite a spike in first-quarter earnings. Revenue fell short of analyst expectations.
Eli Lilly and Co.’s rebound bolsters endowment
The value of Lilly Endowment Inc.’s principal holding—Eli Lilly and Co. stock—has increased nearly $2 billion over the past two years, bolstering the private foundation’s philanthropic firepower after a decade of declining or stagnant assets.
Eli Lilly aims to ramp up social media presence
The drugmaker recently drafted social media guidelines it hopes can help it expand its use of social media to more of its employees—without running afoul of regulators.
Eli Lilly’s top lawyer to retire at end of year
Indianapolis-based drugmaker Eli Lilly and Co. said Thursday its general counsel, Robert Armitage, will retire at the end of the year and be replaced by deputy general counsel Michael Harrington.
Eli Lilly’s Cialis faces faster-acting competition
A Vivus Inc. pill that is supposed to provide erections within 15 minutes, about half the time or less than Eli Lilly and Co.'s Cialis or Pfizer Inc.’s Viagra, has received U.S. regulatory approval.
PROXY CORNER: Eli Lilly and Co.
Indianapolis-based Eli Lilly and Co discovers, develops, manufactures and sells pharmaceutical products for humans and animals.
Eli Lilly unit plans to buy feed-enzyme maker
Drugmaker Eli Lilly and Co.'s Elanco animal health division plans to buy a privately held maker of feed-enzyme products that improve poultry, egg and meat production.
Eli Lilly, Turkish firm in talks to sell drugs in 26 nations
Eli Lilly and Co., the world’s biggest maker of psychiatric drugs, is in talks with Mustafa Nevzat Ilac Sanayii AS to sell the Turkish company’s treatments in 26 countries, said Mustafa Nevzat’s CEO.
Eli Lilly’s Elanco unit blossoming at just the right time
An investment firm projects that the Elanco animal-health business will generate sales of nearly $2 billion by 2012 and surpass $3 billion by 2018.
Eli Lilly using big dividend to prevent investor exodus
Lilly executives are emphatic that they have no plans to reduce the company's 49-cents-a-share quarterly cash dividend, which gives the stock a rich annual yield of 5.2 percent.
Eli Lilly’s slumbering stock finally shows signs of life
Is it finally time to get some growth again out of a stock that since its debut on the public market 59 years ago has minted thousands of millionaires?
Eli Lilly pledges $2.5 million to Mind Trust
Eli Lilly and Co. plans to give $2.5 million toward a new fundraising campaign by the Mind Trust, an Indianapolis-based education reform group.
PROXY CORNER: Eli Lilly and Co.
Eli Lilly and Co., Lilly Corporate Center, Indianapolis, 46285 (www.lilly.com) discovers, develops, manufactures and sells pharmaceutical products for humans and animals.
Eli Lilly neuroscience chief resigns
David Bredt, vice president of neuroscience research, has resigned “to pursue other opportunities,” according to Lilly spokeswoman Judy Kay Moore. Bredt had overseen Lilly’s development of various drugs, including molecules in late-stage human testing to treat Alzheimer’s and depression.
Eli Lilly CEO Lechleiter sees 2010 pay fall 22 percent
Eli Lilly and Co. Chairman and CEO John Lechleiter received compensation valued at $12.7 million last year, down 22 percent from 2009 largely due to a change in how the drugmaker handles equity awards.
Eli Lilly puts faith in drug pipeline
Eli Lilly and Co. started to tip over its massive “patent cliff” this year, yet announced little publicly that will significantly soften its inevitable sales plunge.
Moody’s downgrades long-term ratings for Eli Lilly
Moody’s Investors Service on Monday lowered the long-term ratings of Lilly one notch, to A2 from A1, citing a wave of patent expirations the drugmaker faces in coming years.
Eli Lilly will have to beat odds to meet drug-rollout goals
Eli Lilly and Co. executives have said repeatedly that the company’s bulging pipeline will produce two new drugs per year, beginning in 2013. But only three times in the past six decades has Lilly been able to launch two or more new drugs in back-to-back years.